Does Bacteim (trimethoprim‑sulfamethoxazole) provide coverage for Pseudomonas aeruginosa, Proteus vulgaris, Klebsiella pneumoniae, and Citrobacter freundii?

Bactrim Does NOT Provide Reliable Coverage for All Four Organisms

Bactrim (trimethoprim-sulfamethoxazole) does NOT adequately cover Pseudomonas aeruginosa and has variable activity against the other organisms you listed. While it may have activity against Proteus vulgaris, Klebsiella pneumoniae, and Citrobacter freundii when they are susceptible, resistance rates are significant and Pseudomonas coverage is essentially absent.

Organism-Specific Coverage Analysis

Pseudomonas aeruginosa: NO Coverage

• Pseudomonas is intrinsically resistant to trimethoprim-sulfamethoxazole 1, 2
• Research confirms that P. aeruginosa shows minimal to no susceptibility to TMP-SMX, with the organism being excluded from Bactrim's spectrum of activity 2, 3
• Guidelines consistently recommend antipseudomonal beta-lactams (cefepime, piperacillin-tazobactam, carbapenems) or fluoroquinolones for Pseudomonas infections 4, 5, 6
• Do not use Bactrim for suspected or confirmed Pseudomonas infections

Proteus vulgaris: YES, Usually Covered

• FDA labeling specifically lists Proteus vulgaris as a susceptible organism for urinary tract infections 1
• However, this is primarily for uncomplicated UTIs where high urinary drug concentrations are achieved
• Systemic infections may require alternative agents depending on susceptibility testing

Klebsiella pneumoniae: VARIABLE Coverage

• FDA labeling lists Klebsiella species as susceptible for UTIs 1
• However, resistance rates are concerning: Studies show 71-75% resistance to TMP-SMX among Klebsiella isolates in healthcare settings 7, 8
• Recent data suggests 7-100% susceptibility (>70% in only 7/12 studies) for carbapenemase-producing Klebsiella 9
• Clinical caveat: When Klebsiella IS susceptible to TMP-SMX, the drug can be effective, including for carbapenemase-producing strains 10, 9, 11
• Always obtain susceptibility testing before relying on Bactrim for Klebsiella infections

Citrobacter freundii: LIMITED Coverage

• Citrobacter species have inducible AmpC beta-lactamases that can lead to resistance development during therapy 12
• While not specifically excluded from Bactrim's spectrum, Citrobacter is grouped with Enterobacter and Serratia as organisms with "common" sulfonamide resistance 2
• Not a reliable empiric choice for Citrobacter infections

Clinical Implications

For empiric therapy covering these organisms, you need:

• Antipseudomonal beta-lactam (cefepime, piperacillin-tazobactam, or carbapenem) for Pseudomonas coverage 4, 5
• Consider adding an aminoglycoside or fluoroquinolone for severe infections or high-risk patients 4

Bactrim may be appropriate ONLY when:

1. Susceptibility testing confirms the organism is sensitive
2. The infection is a uncomplicated UTI (where high urinary concentrations compensate for moderate resistance)
3. Pseudomonas is definitively ruled out
4. You're treating specific susceptible organisms like Stenotrophomonas maltophilia (where TMP-SMX is first-line) 13, 14

Key Pitfalls to Avoid

• Never use Bactrim empirically for suspected Pseudomonas infections - this will result in treatment failure
• Don't assume Klebsiella susceptibility - resistance rates exceed 70% in many settings 7, 8
• Avoid Bactrim monotherapy for serious systemic infections with these organisms without confirmed susceptibility
• Remember that in vitro synergy with other agents (like polymyxin B) has been demonstrated but is not clinically validated for routine use 15